Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980052/S017

TMJ Concepts Patient-Fitted TMJ Reconstruction Prosthesis

Stryker Leibinger GmbH & Co. KG · Decision date Mar 6, 2026

FDA DECISIONP980052/S017

What did the FDA approve?

FDA records P980052/S017 as a supplement to PMA P980052, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Mar 6, 2026.

FDA approval order statement

the implementation of two (2) new sterile barrier heat sealing machines for use in the packaging process of patient-fitted TMJ implant
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Dental
Decision date
Mar 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P980052/S017
Regulatory pathway
PMA supplement
Product code
LZD
Decision code
APPR
Decision date
Mar 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Joint, temporomandibular, implant.

Product code
LZD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P980052/S016 · Related supplement

    TMJ Concepts Patient Fitted Temporomandibular Joint (TMJ) Reconstruction Prosthesis System

  2. P980052/S017 received

    Application receipt date recorded by FDA.

  3. P980052/S017 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P980052. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980052

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker Leibinger GmbH & Co. KGPMA supplementJul 23, 2025FDA

Explore the linked device profile

Other records with product code LZD

Product / regulatory recordCompanyPathwayDecision dateSource
BIOMET MICROFIXATION, INCPMA supplementFeb 19, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stryker Leibinger GmbH & Co. KG

Headquarters
Not reported
Brand website
stryker.com
FDA applicant address
Boetzinger Strasse 41, D-7911, Freiburg, D-7911

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records